Vivani Medical reports wider Q3 net loss

Vivani Medical

13/11/2025 12:52

Overview

Vivani reports Q3 net loss widening to $6.5 mln, with increased operating expenses

Vivani secures $25.7 mln in cash and commitments for development projects

Outlook

Vivani plans Phase 1 study of semaglutide implant in early 2026

Company preparing for Phase 2 study pending Phase 1 results

Vivani expects Cortigent spin-off post-SEC operations resumption

Result Drivers

FUNDING SECURED - Vivani secures $25.7 mln in cash and commitments to support accelerated development of NPM-139

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.11
Q3 Net Income
-$6.53 mln
Q3 Income from Operations
-$6.73 mln
Q3 Operating Expenses
$6.73 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Vivani Medical Inc is $4.00, about 61.7% above its November 12 closing price of $1.53

Press Release: ID:nGNXHJLcl

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)